TB-500 Half-Life, Sequence, and Dosing: A Physician’s Quick Reference

Structural Details

The commonly referenced TB-500 fragment is derived from the actin-binding region of thymosin β-4. The specific amino acid sequence is a 17-residue peptide corresponding to the central actin-interacting portion of the parent protein. Molecular weight is approximately 1.9 kDa.

Distinguishing notes:

• TB-500 refers to the synthetic peptide fragment.
• Thymosin β-4 (Tβ4) refers to the full 43-amino-acid parent protein.
• Some clinical and commercial preparations interchange the terminology, which has caused ongoing confusion in patient-facing materials.

Half-Life Considerations

The half-life profile of TB-500 in circulation is relatively short, consistent with the kinetics of short-chain synthetic peptides. The published pharmacokinetic literature is more limited than for larger peptide therapies, but the clinically relevant framing is:

• Plasma half-life is measured in hours rather than days
• Tissue effects may persist longer than circulating levels, consistent with the intracellular site of action
• Dosing frequency in clinical protocols is typically once daily or a few times per week, depending on the specific formulation

Typical Dosing Frameworks

Dosing in clinical practice varies by:

• Compounding pharmacy formulation
• Clinical indication
• Delivery route (subcutaneous injection is most common)
• Treatment phase (loading versus maintenance)

Common framework patterns referenced in clinical practice include:

• Loading phase: higher-dose frequency (e.g., several times weekly) for the first 4–6 weeks
• Maintenance phase: reduced dosing frequency after loading
• Cycling: 4–8 week treatment cycles with rest periods between

Specific dose magnitudes should be confirmed with the prescribing physician and compounding pharmacy, as formulation-specific guidance is essential.

Subcutaneous vs Other Routes

Subcutaneous injection is the most common delivery route for TB-500. Sublingual and oral formulations exist from some compounding partners but have reduced bioavailability relative to injection. For peptides of this size with limited gastrointestinal stability, injection remains the reference standard.

Storage and Handling

TB-500 is typically provided as a lyophilized powder for reconstitution with bacteriostatic water. Key handling considerations:

• Reconstituted solution is refrigerated
• Stability after reconstitution is typically 30 days with appropriate storage
• Light protection as typical for peptide therapies
• Specific handling should follow the compounding pharmacy’s product monograph

Combined Use Patterns

TB-500 is frequently combined with BPC-157 in tissue-repair protocols. The combination is often termed “BPC + TB” in clinical practice. The rationale:

• BPC-157 provides angiogenic and anti-inflammatory support
• TB-500 provides actin regulation and cell migration support
• The combination addresses multiple layers of tissue repair biology

Safety Profile

The reported safety profile of TB-500 is generally favorable:

• Minimal serious adverse events in preclinical and clinical experience
• Injection-site reactions are the most commonly reported issue
• Systemic effects are uncommon
• Specific concerns around angiogenesis in cancer contexts warrant caution in selected patients

Key Takeaways

• TB-500 is a 17-amino-acid peptide fragment of thymosin β-4.
• Plasma half-life is measured in hours; tissue effects may persist longer.
• Subcutaneous injection is the standard delivery route.
• Dosing typically involves a loading phase followed by maintenance; cycling is common.
• Combined use with BPC-157 is a frequent clinical pattern for tissue repair protocols.
• The reported safety profile is favorable with appropriate patient selection.

Frequently Asked Questions

What is the half-life of TB-500?

Plasma half-life is measured in hours; exact published values vary. Tissue effects may outlast circulating levels.

What is the TB-500 peptide sequence?

TB-500 is a 17-residue synthetic peptide derived from the actin-binding region of thymosin β-4.

How often is TB-500 injected?

Typical protocols involve several injections per week during loading phases, reduced to less frequent dosing during maintenance.

Can TB-500 be taken orally?

Sublingual and oral formulations exist, but bioavailability is significantly lower than injection. Injection is the reference standard.